Endocannabinoids 3. Diseases of peripheral organs involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 3, 2002, Pages 335-347

  Di Marzo, Vincenzo ^a   Matias, Isabel ^a   De Petrocellis, Luciano ^a  

^a CNR   (Italy)

Author keywords

2 arachidonoyl glycerol; Anandamide; Cannabinoid; Cardiovascular; Endocannabinoid; Immunity; Intestine; Receptor; Reproduction; Vanilloid

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; ANTIHYPERTENSIVE AGENT; ARVANIL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABINOL; RIMONABANT; UNCLASSIFIED DRUG;

ABORTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIARRHEA; EMBRYO; ENTERITIS; ENTEROPATHY; GENITAL SYSTEM DISEASE; HYPERTENSION; IMMUNOPATHOLOGY; MOUSE; NONHUMAN; RAT; REVIEW; SYMPTOM;

EID: 0036072522     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development
2. The pharmacohistory of Cannabis sativa
3. Endocannabinoids Part I: Molecular basis of endocannabinoid formation, activation and inactivation and development of selective inhibitors
4. Marijuana and immunity
5. Cannabinoid receptors and the regulation of immune response
6. Endocannabinoids in the immune system and cancer
7. Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes
8. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: Connections with anandamide
9. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): Their affinities for cannabinoid receptors and pathways of inactivation
10. Anandamide hydrolysis by human cells in culture and brain
11. Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor
12. Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors
13. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension
14. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system
15. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoural macrophages
16. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes
17. Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells
18. Anandamide activates human platelets through a pathway independent of the arachidonate cascade
19. Progesterone upregulates anandamide hydrolase in human lymphocytes: Role of cytokines and implications for fertility
20. Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer
21. 2) messenger RNA expression during in vitro stimulation of murine splenocytes with lipopolysaccharide
22. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta
23. Anti-CD40, anti-CD3 and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes
24. 2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation
25. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders
26. The cannabinoid system and cytokine network
27. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through downregulation of the nuclear factor of activated T cells
28. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumour necrosis factor-alpha production in murine macrophages and in mice
29. Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60
30. 2 receptor
31. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells
32. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines
33. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide
34. Effects of the cannabimimetic fatty acid derivatives 2-arachidonoylglycerol, anandamide, palmitoyl-ethanolamide and methanandamide upon IgE-dependent antigen-induced beta-hexosaminidase, RBL-2H3 basophilic leukaemic cells
35. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder
36. Anti-inflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat
37. Cardiovascular effects of endocannabinoids - The plot thickens
38. Endocannabinoids and vascular function
39. Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats
40. Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice
41. 1 receptor
42. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid
43. 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor
44. Human brain capillary endothelium: 2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1
45. Cardiovascular pharmacology of anandamide
46. Anandamide-induced relaxation of sheep coronary arteries: The role of the vascular endothelium, arachidonic acid metabolites and potassium channels
47. 2+ channel current
48. Influence of cannabinoids on the delayed rectifier in freshly dissociated smooth muscle cells of the rat aorta
49. 2 receptors
50. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication
51. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
52. Regional differences in anandamide- and methanandamide-induced membrane potential changes in rat mesenteric arteries
53. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries
54. 1 receptor mRNA in human vascular cells: Is 2-arachidonoylglycerol a possible vasomodulator?
55. Anandamide uptake by human endothelial cells and its regulation by nitric oxide
56. 1 cannabinoid receptors in haemorrhagic shock
57. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis
58. Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat
59. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction
60. Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors
61. Downregulation of anandamide hydrolase in mouse uterus by sex hormones
62. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation
63. Fatty-acid amide hydrolase is expressed in the mouse uterus and embryo during the periim plantation period
64. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage
65. Dysregulated cannabinoid signalling disrupts uterine receptivity for embryo implantation
66. Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction
67. Occurrence and metabolism of anandamide and related acylethanolamides in ovaries of the sea urchin Paracentrotus lividus
68. Inhibition of sea urchin fertilization by fatty acid ethanolamides and cannabinoids
69. Functional cannabinoid receptors in human sperm
70. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
71. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
72. Structure-activity relationship for the endogenous cannabinoid, anandamide and certain of its analogues at vanilloid receptors in transfected cells and vas deferens
73. Cannabinoids and the gastrointestinal tract
74. The gastrointestinal pharmacology of cannabinoids
75. Anandamides: Tolerance and cross-tolerance to delta 9-tetrahydrocannabinol
76. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid
77. Endocannabinoids as physiological regulators of colonic propulsion in mice
78. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation
79. Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine
80. Excitatory transmission to the circular muscle of the guinea-pig ileum: Evidence for the involvement of cannabinoid CB1 receptors
81. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus
82. Modulation of peristalsis by cannabinoid CB(1) ligands in the isolated guinea-pig ileum
83. Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse
84. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice
85. Involvement of the endogenous cannabinoid system in the pathogenesis of digestive ileus in mice
86. HU-308: A specific agonist for CB(2), a peripheral cannabinoid receptor
87. CB2 cannabinoid receptor-mediated peripheral antinociception
88. New perspectives on enigmatic vanilloid receptors
89. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): Vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors
90. Neurobehavioural activity in mice of N-vanillyl-arachidonyl-amide
91. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor 'hybrid' ligands
92. 2 receptors
93. Anandamide receptors
94. Effect of vanilloid drugs on gastrointestinal transit in mice
95. Endocannabinoids 2. CNS pathological conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs
96. Endocannabinoids, hormone-cytokine networks and human fertility
97. Enhancement of erythropoietin-stimulated cell proliferation by Anandamide correlates with increased activation of the mitogen-activated protein kinases ERK1 and ERK2
98. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol
99. 2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures
100. 1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells
101. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells